Corona Remedies IPO sees strong demand with 9.96 times subscription on Day 3
The Corona Remedies IPO has attracted robust investor interest, reaching 9.96 times subscription by Day 3. The strong demand across categories and an active grey market premium have put the spotlight on whether investors should consider applying.
The public issue of Corona Remedies continued to gain strong traction on its third day, with total subscription reaching 9.96 times. The company, which operates in the pharmaceutical sector, has drawn interest from retail investors, institutional buyers and non institutional investors.
Data shows that the retail portion saw brisk participation, while non institutional investors oversubscribed their quota significantly. Qualified institutional buyers also contributed to the strong overall response, signalling confidence in the company’s growth prospects.
Market observers noted that the grey market premium remained active, indicating positive sentiment ahead of the listing. While GMP trends do not guarantee performance, they often reflect investor expectation of potential listing gains.
Corona Remedies is known for its diversified pharmaceutical portfolio, steady revenue growth and expanding distribution network. Analysts believe that the company’s presence in chronic and acute therapy segments adds to its long term potential. However, they also caution that the pharma sector remains highly competitive and margins can fluctuate due to regulatory pressure and raw material costs.
For investors evaluating whether to apply, factors such as valuation, financial stability, demand indicators and long term growth potential are important. The strong subscription levels suggest broad market confidence, but individual risk appetite and investment horizon should be considered before making a final decision.
With the issue closing soon, attention now turns to final subscription numbers and potential listing expectations. The strong Day 3 performance has already positioned the Corona Remedies IPO as one of the more actively followed offerings in the current market cycle.
About the Author
